ANNE
BEST
All components provided with ANNEThe device is currently under FDA review, and in collaboration with Sibel Health, an Investigational Testing Authorization (ITA) was obtained with Health Canada to test the monitoring system in this study.The standard monitoring technology used as a reference will be the Philips Intellivue monitor (Intellivue MX450; Philips Healthcare, Best, Netherlands) connected to ECG leads (NeotrodeThe study will be performed in two phases. In phase 1, infants will undergo monitoring for a period of 8 h per day during daytime (from 8 am to 4 pm or from 9 am to 5 pm) and for 4 consecutive days. In phase 2, another group of infants selected based on the same postmenstrual age and clinical criteria as used in phase 1, will undergo monitoring for a period of 96 h continuously (In phase 1, the study equipment will be placed into the patient room and two wireless sensors will be applied to the infant’s skin, one at the chest and the other one at the limb. In phase 2, an additional wireless sensor will be applied at the abdominal wall for acquisition of abdominal movements. The types of sensors to be used in each phase are shown in 